- Home
- PDX vs RCUS Comparison
PDX vs RCUS Comparison
Compare PDX & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDX
- RCUS
- Stock Information
- Founded
- PDX 2019
- RCUS 2015
- Country
- PDX NY
- RCUS United States
- Employees
- PDX N/A
- RCUS N/A
- Industry
- PDX Finance/Investors Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- PDX Finance
- RCUS Health Care
- Exchange
- PDX Nasdaq
- RCUS Nasdaq
- Market Cap
- PDX 1.2B
- RCUS 1.4B
- IPO Year
- PDX N/A
- RCUS 2018
- Fundamental
- Price
- PDX $31.82
- RCUS $14.15
- Analyst Decision
- PDX
- RCUS Buy
- Analyst Count
- PDX 0
- RCUS 12
- Target Price
- PDX N/A
- RCUS $34.50
- AVG Volume (30 Days)
- PDX N/A
- RCUS 583.4K
- Earning Date
- PDX 01-01-0001
- RCUS 02-19-2025
- Dividend Yield
- PDX 4.95%
- RCUS N/A
- EPS Growth
- PDX N/A
- RCUS N/A
- EPS
- PDX N/A
- RCUS N/A
- Revenue
- PDX N/A
- RCUS $263,000,000.00
- Revenue This Year
- PDX N/A
- RCUS $127.65
- Revenue Next Year
- PDX N/A
- RCUS N/A
- P/E Ratio
- PDX N/A
- RCUS N/A
- Revenue Growth
- PDX N/A
- RCUS 119.17
- 52 Week Low
- PDX $13.52
- RCUS $13.51
- 52 Week High
- PDX $21.05
- RCUS $20.31
- Technical
- Relative Strength Index (RSI)
- PDX 73.23
- RCUS 39.00
- Support Level
- PDX $30.73
- RCUS $13.81
- Resistance Level
- PDX $32.65
- RCUS $14.45
- Average True Range (ATR)
- PDX 1.05
- RCUS 0.57
- MACD
- PDX 0.60
- RCUS -0.06
- Stochastic Oscillator
- PDX 85.17
- RCUS 30.40
About PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited term, closed-end management investment company registered under the Investment Company. The fund's primary investment objective is to seek current income as a primary objective and capital appreciation as a secondary objective.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.